Drug classthatrevolutionizedCMLtreatmentPercentageof blastspresent inthe blastphaseTherecommendedcriteria usedfor acceleratedphaseTranslocationbetweenthese twochromosomesoccur in CMLThelandmarkfor thefirst TKINumber ofblastspresent inacceleratedphaseThe scoringsystem usedin chronicphaseToo many ofthese bloodcells areabnormal inCMLI have theT315I mutationbut also haveelevated lipaseWhen togive H2RAswithdasatinibThis TKI hasthe mostmetabolicsyndromeNon-pharmacologicaltreatment forCMLModerateto highemetogenicrisk TKIsPatients havepresence of thisBCR-ABLproteinindicative ofCML I failed 3lines of TKIs,I can try thisagent nextTKIs aremajorsubstratesfor this liverenzymeTreatmentfor blastphaseCMLI want toavoid thisTKI if I donot wantdiarrheaThe current5-yearoverallsurvival rateof CMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibAfter 3months, I have3% BCR-ABL,I have this TKIresponse60-70% ofpatients withCML presentwith thissymptomResponsewhen BCR-ABL1 (IS)is <0.01%The numberof distinctclinicalphases inCMLDrug classthatrevolutionizedCMLtreatmentPercentageof blastspresent inthe blastphaseTherecommendedcriteria usedfor acceleratedphaseTranslocationbetweenthese twochromosomesoccur in CMLThelandmarkfor thefirst TKINumber ofblastspresent inacceleratedphaseThe scoringsystem usedin chronicphaseToo many ofthese bloodcells areabnormal inCMLI have theT315I mutationbut also haveelevated lipaseWhen togive H2RAswithdasatinibThis TKI hasthe mostmetabolicsyndromeNon-pharmacologicaltreatment forCMLModerateto highemetogenicrisk TKIsPatients havepresence of thisBCR-ABLproteinindicative ofCML I failed 3lines of TKIs,I can try thisagent nextTKIs aremajorsubstratesfor this liverenzymeTreatmentfor blastphaseCMLI want toavoid thisTKI if I donot wantdiarrheaThe current5-yearoverallsurvival rateof CMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibAfter 3months, I have3% BCR-ABL,I have this TKIresponse60-70% ofpatients withCML presentwith thissymptomResponsewhen BCR-ABL1 (IS)is <0.01%The numberof distinctclinicalphases inCML

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
N
2
B
3
N
4
G
5
G
6
O
7
B
8
N
9
N
10
G
11
O
12
O
13
G
14
B
15
O
16
I
17
I
18
B
19
I
20
I
21
I
22
G
23
B
24
O
  1. N-Drug class that revolutionized CML treatment
  2. B-Percentage of blasts present in the blast phase
  3. N-The recommended criteria used for accelerated phase
  4. G-Translocation between these two chromosomes occur in CML
  5. G-The landmark for the first TKI
  6. O-Number of blasts present in accelerated phase
  7. B-The scoring system used in chronic phase
  8. N-Too many of these blood cells are abnormal in CML
  9. N-I have the T315I mutation but also have elevated lipase
  10. G-When to give H2RAs with dasatinib
  11. O-This TKI has the most metabolic syndrome
  12. O-Non-pharmacological treatment for CML
  13. G-Moderate to high emetogenic risk TKIs
  14. B-Patients have presence of this BCR-ABL protein indicative of CML
  15. O-I failed 3 lines of TKIs, I can try this agent next
  16. I-TKIs are major substrates for this liver enzyme
  17. I-Treatment for blast phase CML
  18. B-I want to avoid this TKI if I do not want diarrhea
  19. I-The current 5-year overall survival rate of CML
  20. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  21. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  22. G-60-70% of patients with CML present with this symptom
  23. B-Response when BCR-ABL1 (IS) is <0.01%
  24. O-The number of distinct clinical phases in CML